DexCom Files 8-K on Financials

TL;DR

DexCom dropped an 8-K on Jan 13, 2025, with financial updates. Check it out.

AI Summary

DexCom, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report date and earliest event reported both being January 13, 2025. The company is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing provides investors with updated information on DexCom's financial performance and condition, which can influence investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual or immediate risks.

Key Players & Entities

• DEXCOM INC (company) — Registrant
• January 13, 2025 (date) — Report Date
• San Diego, CA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global

Filing Documents

• dxcm-20250113.htm (8-K) — 31KB
• dxcm991_1132025.htm (EX-99.1) — 10KB
• dxcm-20250113_g1.jpg (GRAPHIC) — 108KB
• 0001093557-25-000004.txt ( ) — 415KB
• dxcm-20250113.xsd (EX-101.SCH) — 2KB
• dxcm-20250113_lab.xml (EX-101.LAB) — 21KB
• dxcm-20250113_pre.xml (EX-101.PRE) — 12KB
• dxcm-20250113_htm.xml (XML) — 3KB

02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. In connection with remarks to be made at the J.P. Morgan 43rd Annual Healthcare Conference on Monday, January 13, 2025, beginning at 12:00 p.m. (Eastern Time), DexCom, Inc. ("Dexcom") Chairman, President and Chief Executive Officer, Kevin Sayer, will report preliminary, unaudited financial results for the fourth quarter of 2024 and fiscal year 2024, initial financial outlook for fiscal year 2025, and certain other information. The fourth quarter and fiscal year 2024 preliminary unaudited financial results contained in Mr. Sayer's presentation, the press release and this Current Report on Form 8-K are subject to finalization in connection with the preparation of Dexcom's Annual Report on Form 10-K for the twelve months ended December 31, 2024. This Current Report on Form 8-K and the press release contain, and Mr. Sayer's presentation on January 13, 2025 will contain, forward-looking statements that are not purely historical regarding Dexcom's or its management's intentions, beliefs, expectations and strategies for the future, including those related to Dexcom's preliminary, unaudited revenue for the fourth quarter of and the full fiscal year 2024, including growth rates; total revenue guidance for fiscal 2025; Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance for fiscal 2024 and 2025, including expected growth rates; and potential strategic and business opportunities. All forward-looking statements included in Mr. Sayer's presentation, the press release and in this Current Report on Form 8-K are made as of the date published, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and therefore are subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from

01. FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. Number Description 99.1 Press release dated January 13, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DEXCOM, INC. By: /s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) Date: January 13, 2025

View Full Filing

View this 8-K filing on SEC EDGAR